Future perspectives in melanoma research “Melanoma Bridge”, Napoli, November 30th–3rd December 2016 View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2017-11-16

AUTHORS

Paolo A. Ascierto, Sanjiv S. Agarwala, Gennaro Ciliberto, Sandra Demaria, Reinhard Dummer, Connie P. M. Duong, Soldano Ferrone, Silvia C. Formenti, Claus Garbe, Ruth Halaban, Samir Khleif, Jason J. Luke, Lluis M. Mir, Willem W. Overwijk, Michael Postow, Igor Puzanov, Paul Sondel, Janis M. Taube, Per Thor Straten, David F. Stroncek, Jennifer A. Wargo, Hassane Zarour, Magdalena Thurin

ABSTRACT

Major advances have been made in the treatment of cancer with targeted therapy and immunotherapy; several FDA-approved agents with associated improvement of 1-year survival rates became available for stage IV melanoma patients. Before 2010, the 1-year survival were quite low, at 30%; in 2011, the rise to nearly 50% in the setting of treatment with Ipilimumab, and rise to 70% with BRAF inhibitor monotherapy in 2013 was observed. Even more impressive are 1-year survival rates considering combination strategies with both targeted therapy and immunotherapy, now exceeding 80%. Can we improve response rates even further, and bring these therapies to more patients? In fact, despite these advances, responses are heterogeneous and are not always durable. There is a critical need to better understand who will benefit from therapy, as well as proper timing, sequence and combination of different therapeutic agents. How can we better understand responses to therapy and optimize treatment regimens? The key to better understanding therapy and to optimizing responses is with insights gained from responses to targeted therapy and immunotherapy through translational research in human samples. Combination therapies including chemotherapy, radiotherapy, targeted therapy, electrochemotherapy with immunotherapy agents such as Immune Checkpoint Blockers are under investigation but there is much room for improvement. Adoptive T cell therapy including tumor infiltrating lymphocytes and chimeric antigen receptor modified T cells therapy is also efficacious in metastatic melanoma and outcome enhancement seem likely by improved homing capacity of chemokine receptor transduced T cells. Tumor infiltrating lymphocytes therapy is also efficacious in metastatic melanoma and outcome enhancement seem likely by improved homing capacity of chemokine receptor transduced T cells. Understanding the mechanisms behind the development of acquired resistance and tests for biomarkers for treatment decisions are also under study and will offer new opportunities for more efficient combination therapies. Knowledge of immunologic features of the tumor microenvironment associated with response and resistance will improve the identification of patients who will derive the most benefit from monotherapy and might reveal additional immunologic determinants that could be targeted in combination with checkpoint blockade. The future of advanced melanoma needs to involve education and trials, biobanks with a focus on primary tumors, bioinformatics and empowerment of patients and clinicians. More... »

PAGES

236

References to SciGraph publications

  • 2015-01-15. Intratumoral electroporation of plasmid interleukin-12: efficacy and biomarker analyses from a phase 2 study in melanoma (OMS-I100) in JOURNAL OF TRANSLATIONAL MEDICINE
  • 2013-07-29. Mining the mutanome: developing highly personalized Immunotherapies based on mutational analysis of tumors in JOURNAL FOR IMMUNOTHERAPY OF CANCER
  • 2013-03-08. Do BRAF inhibitors select for populations with different disease progression kinetics? in JOURNAL OF TRANSLATIONAL MEDICINE
  • 2016-03-18. The promising alliance of anti-cancer electrochemotherapy with immunotherapy in CANCER AND METASTASIS REVIEWS
  • 2012-07-29. Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma in NATURE GENETICS
  • 2008. Physical Activity and Cancer Prevention in SPORTS MEDICINE
  • 2012-05-03. The role of BRAF V600 mutation in melanoma in JOURNAL OF TRANSLATIONAL MEDICINE
  • 2006-06-17. Immune selective pressure and HLA class I antigen defects in malignant lesions in CANCER IMMUNOLOGY, IMMUNOTHERAPY
  • 2012-05-07. Mechanisms of acquired resistance to ERK1/2 pathway inhibitors in ONCOGENE
  • 2013-07-27. Activation of an early feedback survival loop involving phospho-ErbB3 is a general response of melanoma cells to RAF/MEK inhibition and is abrogated by anti-ErbB3 antibodies in JOURNAL OF TRANSLATIONAL MEDICINE
  • 2016-06-13. Immune checkpoint blockade with concurrent electrochemotherapy in advanced melanoma: a retrospective multicenter analysis in CANCER IMMUNOLOGY, IMMUNOTHERAPY
  • 2016-03-28. Integrated digital error suppression for improved detection of circulating tumor DNA in NATURE BIOTECHNOLOGY
  • 2013-03-03. Persistent antigen at vaccination sites induces tumor-specific CD8+ T cell sequestration, dysfunction and deletion in NATURE MEDICINE
  • 2015-03-30. Robust enumeration of cell subsets from tissue expression profiles in NATURE METHODS
  • 2015-05-11. Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity in NATURE
  • 2016-08-29. Large-scale detection of antigen-specific T cells using peptide-MHC-I multimers labeled with DNA barcodes in NATURE BIOTECHNOLOGY
  • 2017-08-15. Agonist anti-GITR antibody significantly enhances the therapeutic efficacy of Listeria monocytogenes-based immunotherapy in JOURNAL FOR IMMUNOTHERAPY OF CANCER
  • 2015-03-06. Balancing natural killer cell activation through paired receptors in NATURE REVIEWS IMMUNOLOGY
  • 2016-07-05. Expression of PD-L1 and HLA Class I in Esophageal Squamous Cell Carcinoma: Prognostic Factors for Patient Outcome in ANNALS OF SURGICAL ONCOLOGY
  • 2016-09-20. Adjuvants for peptide-based cancer vaccines in JOURNAL FOR IMMUNOTHERAPY OF CANCER
  • 2017-06-09. DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity in NATURE COMMUNICATIONS
  • 2014-10-28. Phase 2 Study of Intralesional PV-10 in Refractory Metastatic Melanoma in ANNALS OF SURGICAL ONCOLOGY
  • 2015-11-04. Exercise suppresses tumor growth through epinephrine- and IL-6-dependent mobilization and redistribution of NK cells in JOURNAL FOR IMMUNOTHERAPY OF CANCER
  • 2016-09-20. Current clinical trials testing the combination of immunotherapy with radiotherapy in JOURNAL FOR IMMUNOTHERAPY OF CANCER
  • 2015-11-04. Phase II calm extension study: Coxsackievirus A21 delivered intratumorally to patients with advanced melanoma induces immune-cell infiltration in the tumor microenvironment in JOURNAL FOR IMMUNOTHERAPY OF CANCER
  • 2013-06-18. Control of pathogens and pathobionts by the gut microbiota in NATURE IMMUNOLOGY
  • 2015-05. Complete regression of melanoma skin metastases after electrochemotherapy plus ipilimumab treatment: an unusual clinical presentation in EUROPEAN JOURNAL OF DERMATOLOGY
  • 2012-07-04. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion in NATURE
  • 2015-06-07. Intratumoral immunotherapy for melanoma in CANCER IMMUNOLOGY, IMMUNOTHERAPY
  • Journal

    TITLE

    Journal of Translational Medicine

    ISSUE

    1

    VOLUME

    15

    Author Affiliations

  • Istituto Nazionale Tumori di Napoli Fondazione “G. Pascale”, Via Mariano Semmola, 80131, Naples, Italy
  • Oncology & Hematology, St. Luke’s University Hospital and Temple University, Bethlehem, PA, USA
  • IRCCS “Regina Elena” National Cancer Institute, Rome, Italy
  • Radiation Oncology and Pathology, Weill Cornell Medical College, New York City, NY, USA
  • Department of Dermatology, University of Zurich Hospital, Zurich, Switzerland
  • INSERM (National Institute of Health and Medical Research), Institut Gustave Roussy, Villejuif, France
  • Massachusetts General Hospital, Boston, MA, USA
  • Department of Radiation Oncology, Weill Cornell Medical College, New York City, NY, USA
  • Division of Dermatologic Oncology, Department of Dermatology, Eberhard Karls University, Tübingen, Germany
  • Department of Dermatology, Yale University School of Medicine, New Haven, CT, USA
  • Georgia Cancer Center, Augusta University, Augusta, GA, USA
  • Department of Hematology/Oncology, University of Chicago Comprehensive Cancer Center, Chicago, IL, USA
  • CNRS (National Center for Scientific Research, France), University Paris-Saclay, Gustave Roussy, Villejuif, France
  • Division of Cancer Medicine, Department of Melanoma Medical Oncology-Research, University of Texas MD Anderson Cancer Center, Houston, TX, USA
  • Weill Cornell Medical College, New York, NY, USA
  • Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA
  • UW Carbone Cancer Center, Madison, WI, USA
  • Johns Hopkins University School of Medicine, Baltimore, MD, USA
  • Department of Immunology and Microbiology, University of Copenhagen, Herlev, Denmark
  • Clinical Center, National Institutes of Health, Bethesda, MD, USA
  • Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
  • Medicine, Immunology and Dermatology Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
  • Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, NCI, NIH, Rockville, MD, USA
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1186/s12967-017-1341-2

    DOI

    http://dx.doi.org/10.1186/s12967-017-1341-2

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1092735344

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/29145885


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1107", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Immunology", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Oncology and Carcinogenesis", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Biomedical Research", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Cancer Vaccines", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Combined Modality Therapy", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "History, 21st Century", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Immunotherapy", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Italy", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Lymphocytes, Tumor-Infiltrating", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Melanoma", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Precision Medicine", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Systems Biology", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "T-Lymphocytes", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Translational Research, Biomedical", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Istituto Nazionale Tumori di Napoli Fondazione \u201cG. Pascale\u201d, Via Mariano Semmola, 80131, Naples, Italy", 
              "id": "http://www.grid.ac/institutes/grid.508451.d", 
              "name": [
                "Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, IRCCS Istituto Nazionale Tumori \u201cFondazione G. Pascale\u201d, Naples, Italy", 
                "Istituto Nazionale Tumori di Napoli Fondazione \u201cG. Pascale\u201d, Via Mariano Semmola, 80131, Naples, Italy"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Ascierto", 
            "givenName": "Paolo A.", 
            "id": "sg:person.01212502023.44", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01212502023.44"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Oncology & Hematology, St. Luke\u2019s University Hospital and Temple University, Bethlehem, PA, USA", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "Oncology & Hematology, St. Luke\u2019s University Hospital and Temple University, Bethlehem, PA, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Agarwala", 
            "givenName": "Sanjiv S.", 
            "id": "sg:person.01160762514.70", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01160762514.70"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "IRCCS \u201cRegina Elena\u201d National Cancer Institute, Rome, Italy", 
              "id": "http://www.grid.ac/institutes/grid.417520.5", 
              "name": [
                "IRCCS \u201cRegina Elena\u201d National Cancer Institute, Rome, Italy"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Ciliberto", 
            "givenName": "Gennaro", 
            "id": "sg:person.01275000143.77", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01275000143.77"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Radiation Oncology and Pathology, Weill Cornell Medical College, New York City, NY, USA", 
              "id": "http://www.grid.ac/institutes/grid.5386.8", 
              "name": [
                "Radiation Oncology and Pathology, Weill Cornell Medical College, New York City, NY, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Demaria", 
            "givenName": "Sandra", 
            "id": "sg:person.01040377132.58", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01040377132.58"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Dermatology, University of Zurich Hospital, Zurich, Switzerland", 
              "id": "http://www.grid.ac/institutes/grid.412004.3", 
              "name": [
                "Department of Dermatology, University of Zurich Hospital, Zurich, Switzerland"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Dummer", 
            "givenName": "Reinhard", 
            "id": "sg:person.01301465365.05", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01301465365.05"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "INSERM (National Institute of Health and Medical Research), Institut Gustave Roussy, Villejuif, France", 
              "id": "http://www.grid.ac/institutes/grid.14925.3b", 
              "name": [
                "INSERM (National Institute of Health and Medical Research), Institut Gustave Roussy, Villejuif, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Duong", 
            "givenName": "Connie P. M.", 
            "id": "sg:person.0757652731.20", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0757652731.20"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Massachusetts General Hospital, Boston, MA, USA", 
              "id": "http://www.grid.ac/institutes/grid.32224.35", 
              "name": [
                "Massachusetts General Hospital, Boston, MA, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Ferrone", 
            "givenName": "Soldano", 
            "id": "sg:person.01261361112.98", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01261361112.98"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Radiation Oncology, Weill Cornell Medical College, New York City, NY, USA", 
              "id": "http://www.grid.ac/institutes/grid.5386.8", 
              "name": [
                "Department of Radiation Oncology, Weill Cornell Medical College, New York City, NY, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Formenti", 
            "givenName": "Silvia C.", 
            "id": "sg:person.010720752277.37", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010720752277.37"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Division of Dermatologic Oncology, Department of Dermatology, Eberhard Karls University, T\u00fcbingen, Germany", 
              "id": "http://www.grid.ac/institutes/grid.10392.39", 
              "name": [
                "Division of Dermatologic Oncology, Department of Dermatology, Eberhard Karls University, T\u00fcbingen, Germany"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Garbe", 
            "givenName": "Claus", 
            "id": "sg:person.01221773122.43", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01221773122.43"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Dermatology, Yale University School of Medicine, New Haven, CT, USA", 
              "id": "http://www.grid.ac/institutes/grid.47100.32", 
              "name": [
                "Department of Dermatology, Yale University School of Medicine, New Haven, CT, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Halaban", 
            "givenName": "Ruth", 
            "id": "sg:person.053601122.01", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.053601122.01"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Georgia Cancer Center, Augusta University, Augusta, GA, USA", 
              "id": "http://www.grid.ac/institutes/grid.410427.4", 
              "name": [
                "Georgia Cancer Center, Augusta University, Augusta, GA, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Khleif", 
            "givenName": "Samir", 
            "id": "sg:person.01240104744.46", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01240104744.46"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Hematology/Oncology, University of Chicago Comprehensive Cancer Center, Chicago, IL, USA", 
              "id": "http://www.grid.ac/institutes/grid.170205.1", 
              "name": [
                "Department of Hematology/Oncology, University of Chicago Comprehensive Cancer Center, Chicago, IL, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Luke", 
            "givenName": "Jason J.", 
            "id": "sg:person.01236071027.04", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01236071027.04"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "CNRS (National Center for Scientific Research, France), University Paris-Saclay, Gustave Roussy, Villejuif, France", 
              "id": "http://www.grid.ac/institutes/grid.14925.3b", 
              "name": [
                "CNRS (National Center for Scientific Research, France), University Paris-Saclay, Gustave Roussy, Villejuif, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Mir", 
            "givenName": "Lluis M.", 
            "id": "sg:person.01154353457.84", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01154353457.84"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Division of Cancer Medicine, Department of Melanoma Medical Oncology-Research, University of Texas MD Anderson Cancer Center, Houston, TX, USA", 
              "id": "http://www.grid.ac/institutes/grid.240145.6", 
              "name": [
                "Division of Cancer Medicine, Department of Melanoma Medical Oncology-Research, University of Texas MD Anderson Cancer Center, Houston, TX, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Overwijk", 
            "givenName": "Willem W.", 
            "id": "sg:person.0717300507.99", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0717300507.99"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Weill Cornell Medical College, New York, NY, USA", 
              "id": "http://www.grid.ac/institutes/grid.5386.8", 
              "name": [
                "Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, NY, USA", 
                "Weill Cornell Medical College, New York, NY, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Postow", 
            "givenName": "Michael", 
            "id": "sg:person.0663446543.06", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0663446543.06"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA", 
              "id": "http://www.grid.ac/institutes/grid.240614.5", 
              "name": [
                "Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Puzanov", 
            "givenName": "Igor", 
            "id": "sg:person.0640153517.24", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0640153517.24"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "UW Carbone Cancer Center, Madison, WI, USA", 
              "id": "http://www.grid.ac/institutes/grid.412639.b", 
              "name": [
                "Pediatrics, Human Oncology and Genetics, University of Wisconsin, Madison, WI, USA", 
                "UW Carbone Cancer Center, Madison, WI, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Sondel", 
            "givenName": "Paul", 
            "id": "sg:person.01101570400.85", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01101570400.85"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Johns Hopkins University School of Medicine, Baltimore, MD, USA", 
              "id": "http://www.grid.ac/institutes/grid.21107.35", 
              "name": [
                "Johns Hopkins University School of Medicine, Baltimore, MD, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Taube", 
            "givenName": "Janis M.", 
            "id": "sg:person.01047232673.17", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01047232673.17"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Immunology and Microbiology, University of Copenhagen, Herlev, Denmark", 
              "id": "http://www.grid.ac/institutes/grid.5254.6", 
              "name": [
                "Center for Cancer Immune Therapy (CCIT), Department of Hematology, University Hospital Herlev, Herlev, Denmark", 
                "Department of Immunology and Microbiology, University of Copenhagen, Herlev, Denmark"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Thor Straten", 
            "givenName": "Per", 
            "id": "sg:person.01065663541.26", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01065663541.26"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Clinical Center, National Institutes of Health, Bethesda, MD, USA", 
              "id": "http://www.grid.ac/institutes/grid.410305.3", 
              "name": [
                "Clinical Center, National Institutes of Health, Bethesda, MD, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Stroncek", 
            "givenName": "David F.", 
            "id": "sg:person.010511471377.03", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010511471377.03"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA", 
              "id": "http://www.grid.ac/institutes/grid.240145.6", 
              "name": [
                "Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Wargo", 
            "givenName": "Jennifer A.", 
            "id": "sg:person.0637157757.45", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0637157757.45"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Medicine, Immunology and Dermatology Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA", 
              "id": "http://www.grid.ac/institutes/grid.21925.3d", 
              "name": [
                "Medicine, Immunology and Dermatology Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Zarour", 
            "givenName": "Hassane", 
            "id": "sg:person.07421203347.21", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07421203347.21"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, NCI, NIH, Rockville, MD, USA", 
              "id": "http://www.grid.ac/institutes/grid.429651.d", 
              "name": [
                "Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, NCI, NIH, Rockville, MD, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Thurin", 
            "givenName": "Magdalena", 
            "id": "sg:person.01207167603.25", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01207167603.25"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1186/1479-5876-13-s1-o11", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1014959746", 
              "https://doi.org/10.1186/1479-5876-13-s1-o11"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s10555-016-9615-3", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1005576880", 
              "https://doi.org/10.1007/s10555-016-9615-3"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/1479-5876-11-180", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1051715774", 
              "https://doi.org/10.1186/1479-5876-11-180"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/1479-5876-10-85", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1050474099", 
              "https://doi.org/10.1186/1479-5876-10-85"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/s40425-016-0160-y", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1005751518", 
              "https://doi.org/10.1186/s40425-016-0160-y"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/onc.2012.160", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1007888310", 
              "https://doi.org/10.1038/onc.2012.160"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1684/ejd.2015.2522", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1025373346", 
              "https://doi.org/10.1684/ejd.2015.2522"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/2051-1426-3-s2-p343", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1040645387", 
              "https://doi.org/10.1186/2051-1426-3-s2-p343"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nbt.3520", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1042966935", 
              "https://doi.org/10.1038/nbt.3520"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00262-015-1727-z", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1010648370", 
              "https://doi.org/10.1007/s00262-015-1727-z"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/ncomms15618", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1085940279", 
              "https://doi.org/10.1038/ncomms15618"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/2051-1426-3-s2-p246", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1005776800", 
              "https://doi.org/10.1186/2051-1426-3-s2-p246"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00262-006-0183-1", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1041326514", 
              "https://doi.org/10.1007/s00262-006-0183-1"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nri3799", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1048881672", 
              "https://doi.org/10.1038/nri3799"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1245/s10434-014-4169-5", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1009814101", 
              "https://doi.org/10.1245/s10434-014-4169-5"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00262-016-1856-z", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1039598355", 
              "https://doi.org/10.1007/s00262-016-1856-z"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nature11183", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1053677952", 
              "https://doi.org/10.1038/nature11183"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1245/s10434-016-5376-z", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1031102571", 
              "https://doi.org/10.1245/s10434-016-5376-z"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/s40425-016-0156-7", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1011176694", 
              "https://doi.org/10.1186/s40425-016-0156-7"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/1479-5876-11-61", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1013247656", 
              "https://doi.org/10.1186/1479-5876-11-61"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.2165/00007256-200838040-00002", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1015129676", 
              "https://doi.org/10.2165/00007256-200838040-00002"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nmeth.3337", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1004732944", 
              "https://doi.org/10.1038/nmeth.3337"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/2051-1426-1-11", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1011304979", 
              "https://doi.org/10.1186/2051-1426-1-11"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nm.3105", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1008050192", 
              "https://doi.org/10.1038/nm.3105"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/ni.2608", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1043661049", 
              "https://doi.org/10.1038/ni.2608"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nature14404", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1002745775", 
              "https://doi.org/10.1038/nature14404"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/s40425-017-0266-x", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1090960408", 
              "https://doi.org/10.1186/s40425-017-0266-x"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/ng.2359", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1021618497", 
              "https://doi.org/10.1038/ng.2359"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nbt.3662", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1036461196", 
              "https://doi.org/10.1038/nbt.3662"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2017-11-16", 
        "datePublishedReg": "2017-11-16", 
        "description": "Major advances have been made in the treatment of cancer with targeted therapy and immunotherapy; several FDA-approved agents with associated improvement of 1-year survival rates became available for stage IV melanoma patients. Before 2010, the 1-year survival were quite low, at 30%; in 2011, the rise to nearly 50% in the setting of treatment with Ipilimumab, and rise to 70% with BRAF inhibitor monotherapy in 2013 was observed. Even more impressive are 1-year survival rates considering combination strategies with both targeted therapy and immunotherapy, now exceeding 80%. Can we improve response rates even further, and bring these therapies to more patients? In fact, despite these advances, responses are heterogeneous and are not always durable. There is a critical need to better understand who will benefit from therapy, as well as proper timing, sequence and combination of different therapeutic agents. How can we better understand responses to therapy and optimize treatment regimens? The key to better understanding therapy and to optimizing responses is with insights gained from responses to targeted therapy and immunotherapy through translational research in human samples. Combination therapies including chemotherapy, radiotherapy, targeted therapy, electrochemotherapy with immunotherapy agents such as Immune Checkpoint Blockers are under investigation but there is much room for improvement. Adoptive T cell therapy including tumor infiltrating lymphocytes and chimeric antigen receptor modified T cells therapy is also efficacious in metastatic melanoma and outcome enhancement seem likely by improved homing capacity of chemokine receptor transduced T cells. Tumor infiltrating lymphocytes therapy is also efficacious in metastatic melanoma and outcome enhancement seem likely by improved homing capacity of chemokine receptor transduced T cells. Understanding the mechanisms behind the development of acquired resistance and tests for biomarkers for treatment decisions are also under study and will offer new opportunities for more efficient combination therapies. Knowledge of immunologic features of the tumor microenvironment associated with response and resistance will improve the identification of patients who will derive the most benefit from monotherapy and might reveal additional immunologic determinants that could be targeted in combination with checkpoint blockade. The future of advanced melanoma needs to involve education and trials, biobanks with a focus on primary tumors, bioinformatics and empowerment of patients and clinicians.", 
        "genre": "article", 
        "id": "sg:pub.10.1186/s12967-017-1341-2", 
        "isAccessibleForFree": true, 
        "isFundedItemOf": [
          {
            "id": "sg:grant.2438793", 
            "type": "MonetaryGrant"
          }, 
          {
            "id": "sg:grant.2411268", 
            "type": "MonetaryGrant"
          }, 
          {
            "id": "sg:grant.4055452", 
            "type": "MonetaryGrant"
          }
        ], 
        "isPartOf": [
          {
            "id": "sg:journal.1032886", 
            "issn": [
              "1479-5876"
            ], 
            "name": "Journal of Translational Medicine", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "1", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "15"
          }
        ], 
        "keywords": [
          "T-cell therapy", 
          "combination therapy", 
          "metastatic melanoma", 
          "chemokine receptors", 
          "T cells", 
          "homing capacity", 
          "survival rate", 
          "Tumor-Infiltrating Lymphocyte Therapy", 
          "stage IV melanoma patients", 
          "adoptive T-cell therapy", 
          "cell therapy", 
          "BRAF inhibitor monotherapy", 
          "setting of treatment", 
          "immune checkpoint blockers", 
          "identification of patients", 
          "chimeric antigen receptor", 
          "efficient combination therapy", 
          "empowerment of patients", 
          "optimize treatment regimens", 
          "different therapeutic agents", 
          "Melanoma Bridge", 
          "immunotherapy agents", 
          "outcome enhancement", 
          "inhibitor monotherapy", 
          "checkpoint blockers", 
          "checkpoint blockade", 
          "more patients", 
          "lymphocyte therapy", 
          "immunologic features", 
          "melanoma patients", 
          "treatment of cancer", 
          "treatment regimens", 
          "primary tumor", 
          "targeted therapy", 
          "treatment decisions", 
          "response rate", 
          "therapy", 
          "patients", 
          "tumor microenvironment", 
          "immunotherapy", 
          "therapeutic agents", 
          "immunologic determinants", 
          "antigen receptor", 
          "translational research", 
          "melanoma research", 
          "monotherapy", 
          "receptors", 
          "human samples", 
          "combination strategies", 
          "tumors", 
          "melanoma", 
          "understanding therapy", 
          "most benefit", 
          "treatment", 
          "major advances", 
          "proper timing", 
          "agents", 
          "response", 
          "ipilimumab", 
          "regimens", 
          "cells", 
          "chemotherapy", 
          "radiotherapy", 
          "blockers", 
          "critical need", 
          "lymphocytes", 
          "blockade", 
          "cancer", 
          "clinicians", 
          "trials", 
          "electrochemotherapy", 
          "biomarkers", 
          "survival", 
          "FDA", 
          "rate", 
          "future perspectives", 
          "microenvironment", 
          "Biobank", 
          "resistance", 
          "improvement", 
          "setting", 
          "need", 
          "advances", 
          "combination", 
          "determinants", 
          "study", 
          "benefits", 
          "timing", 
          "test", 
          "room", 
          "mechanism", 
          "capacity", 
          "identification", 
          "samples", 
          "development", 
          "strategies", 
          "research", 
          "enhancement", 
          "knowledge", 
          "education", 
          "investigation", 
          "features", 
          "focus", 
          "rise", 
          "new opportunities", 
          "empowerment", 
          "decisions", 
          "insights", 
          "future", 
          "opportunities", 
          "fact", 
          "perspective", 
          "sequence", 
          "Napoli", 
          "bioinformatics", 
          "key", 
          "bridge"
        ], 
        "name": "Future perspectives in melanoma research \u201cMelanoma Bridge\u201d, Napoli, November 30th\u20133rd December 2016", 
        "pagination": "236", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1092735344"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1186/s12967-017-1341-2"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "29145885"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1186/s12967-017-1341-2", 
          "https://app.dimensions.ai/details/publication/pub.1092735344"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2022-11-24T21:01", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20221124/entities/gbq_results/article/article_727.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.1186/s12967-017-1341-2"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s12967-017-1341-2'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s12967-017-1341-2'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s12967-017-1341-2'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s12967-017-1341-2'


     

    This table displays all metadata directly associated to this object as RDF triples.

    575 TRIPLES      21 PREDICATES      185 URIs      147 LITERALS      20 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1186/s12967-017-1341-2 schema:about N0c4e639313e542d68a8d94f3987a1d3e
    2 N1fe1373a85924b6fac0a4bda104461cf
    3 N26c329507caf4f6989edb1f105f237fc
    4 N7cb8be9ddb124677be02834e032c3f54
    5 N90f10fdb9a294e65914595d16595f9cc
    6 N9fb8bb4217944a4aa4cfdd5975b80f73
    7 Nad1322073ede48ee93182e8d9f422663
    8 Nb24b7f528acc428ebf7ebae694735d38
    9 Nd0d9483b0d3545158e707e7cc2bdc3ce
    10 Nd59e5ee1e58f4a809dd538fb751a8251
    11 Ndad0751c558c49e09dd3db447429b614
    12 Ne0c2ae21e61548899321d79151302036
    13 Ne4ebbb4426024e0283867d803a76fe58
    14 anzsrc-for:11
    15 anzsrc-for:1107
    16 anzsrc-for:1112
    17 schema:author N93202783dd9543cc8f0d4b65a0580f4a
    18 schema:citation sg:pub.10.1007/s00262-006-0183-1
    19 sg:pub.10.1007/s00262-015-1727-z
    20 sg:pub.10.1007/s00262-016-1856-z
    21 sg:pub.10.1007/s10555-016-9615-3
    22 sg:pub.10.1038/nature11183
    23 sg:pub.10.1038/nature14404
    24 sg:pub.10.1038/nbt.3520
    25 sg:pub.10.1038/nbt.3662
    26 sg:pub.10.1038/ncomms15618
    27 sg:pub.10.1038/ng.2359
    28 sg:pub.10.1038/ni.2608
    29 sg:pub.10.1038/nm.3105
    30 sg:pub.10.1038/nmeth.3337
    31 sg:pub.10.1038/nri3799
    32 sg:pub.10.1038/onc.2012.160
    33 sg:pub.10.1186/1479-5876-10-85
    34 sg:pub.10.1186/1479-5876-11-180
    35 sg:pub.10.1186/1479-5876-11-61
    36 sg:pub.10.1186/1479-5876-13-s1-o11
    37 sg:pub.10.1186/2051-1426-1-11
    38 sg:pub.10.1186/2051-1426-3-s2-p246
    39 sg:pub.10.1186/2051-1426-3-s2-p343
    40 sg:pub.10.1186/s40425-016-0156-7
    41 sg:pub.10.1186/s40425-016-0160-y
    42 sg:pub.10.1186/s40425-017-0266-x
    43 sg:pub.10.1245/s10434-014-4169-5
    44 sg:pub.10.1245/s10434-016-5376-z
    45 sg:pub.10.1684/ejd.2015.2522
    46 sg:pub.10.2165/00007256-200838040-00002
    47 schema:datePublished 2017-11-16
    48 schema:datePublishedReg 2017-11-16
    49 schema:description Major advances have been made in the treatment of cancer with targeted therapy and immunotherapy; several FDA-approved agents with associated improvement of 1-year survival rates became available for stage IV melanoma patients. Before 2010, the 1-year survival were quite low, at 30%; in 2011, the rise to nearly 50% in the setting of treatment with Ipilimumab, and rise to 70% with BRAF inhibitor monotherapy in 2013 was observed. Even more impressive are 1-year survival rates considering combination strategies with both targeted therapy and immunotherapy, now exceeding 80%. Can we improve response rates even further, and bring these therapies to more patients? In fact, despite these advances, responses are heterogeneous and are not always durable. There is a critical need to better understand who will benefit from therapy, as well as proper timing, sequence and combination of different therapeutic agents. How can we better understand responses to therapy and optimize treatment regimens? The key to better understanding therapy and to optimizing responses is with insights gained from responses to targeted therapy and immunotherapy through translational research in human samples. Combination therapies including chemotherapy, radiotherapy, targeted therapy, electrochemotherapy with immunotherapy agents such as Immune Checkpoint Blockers are under investigation but there is much room for improvement. Adoptive T cell therapy including tumor infiltrating lymphocytes and chimeric antigen receptor modified T cells therapy is also efficacious in metastatic melanoma and outcome enhancement seem likely by improved homing capacity of chemokine receptor transduced T cells. Tumor infiltrating lymphocytes therapy is also efficacious in metastatic melanoma and outcome enhancement seem likely by improved homing capacity of chemokine receptor transduced T cells. Understanding the mechanisms behind the development of acquired resistance and tests for biomarkers for treatment decisions are also under study and will offer new opportunities for more efficient combination therapies. Knowledge of immunologic features of the tumor microenvironment associated with response and resistance will improve the identification of patients who will derive the most benefit from monotherapy and might reveal additional immunologic determinants that could be targeted in combination with checkpoint blockade. The future of advanced melanoma needs to involve education and trials, biobanks with a focus on primary tumors, bioinformatics and empowerment of patients and clinicians.
    50 schema:genre article
    51 schema:isAccessibleForFree true
    52 schema:isPartOf N79b273df1eb24e5fa4f26de6bf9592a7
    53 Nb6ca6a4d49bf45fba24358d14335c274
    54 sg:journal.1032886
    55 schema:keywords BRAF inhibitor monotherapy
    56 Biobank
    57 FDA
    58 Melanoma Bridge
    59 Napoli
    60 T cells
    61 T-cell therapy
    62 Tumor-Infiltrating Lymphocyte Therapy
    63 adoptive T-cell therapy
    64 advances
    65 agents
    66 antigen receptor
    67 benefits
    68 bioinformatics
    69 biomarkers
    70 blockade
    71 blockers
    72 bridge
    73 cancer
    74 capacity
    75 cell therapy
    76 cells
    77 checkpoint blockade
    78 checkpoint blockers
    79 chemokine receptors
    80 chemotherapy
    81 chimeric antigen receptor
    82 clinicians
    83 combination
    84 combination strategies
    85 combination therapy
    86 critical need
    87 decisions
    88 determinants
    89 development
    90 different therapeutic agents
    91 education
    92 efficient combination therapy
    93 electrochemotherapy
    94 empowerment
    95 empowerment of patients
    96 enhancement
    97 fact
    98 features
    99 focus
    100 future
    101 future perspectives
    102 homing capacity
    103 human samples
    104 identification
    105 identification of patients
    106 immune checkpoint blockers
    107 immunologic determinants
    108 immunologic features
    109 immunotherapy
    110 immunotherapy agents
    111 improvement
    112 inhibitor monotherapy
    113 insights
    114 investigation
    115 ipilimumab
    116 key
    117 knowledge
    118 lymphocyte therapy
    119 lymphocytes
    120 major advances
    121 mechanism
    122 melanoma
    123 melanoma patients
    124 melanoma research
    125 metastatic melanoma
    126 microenvironment
    127 monotherapy
    128 more patients
    129 most benefit
    130 need
    131 new opportunities
    132 opportunities
    133 optimize treatment regimens
    134 outcome enhancement
    135 patients
    136 perspective
    137 primary tumor
    138 proper timing
    139 radiotherapy
    140 rate
    141 receptors
    142 regimens
    143 research
    144 resistance
    145 response
    146 response rate
    147 rise
    148 room
    149 samples
    150 sequence
    151 setting
    152 setting of treatment
    153 stage IV melanoma patients
    154 strategies
    155 study
    156 survival
    157 survival rate
    158 targeted therapy
    159 test
    160 therapeutic agents
    161 therapy
    162 timing
    163 translational research
    164 treatment
    165 treatment decisions
    166 treatment of cancer
    167 treatment regimens
    168 trials
    169 tumor microenvironment
    170 tumors
    171 understanding therapy
    172 schema:name Future perspectives in melanoma research “Melanoma Bridge”, Napoli, November 30th–3rd December 2016
    173 schema:pagination 236
    174 schema:productId N30a65ba628204a2998da52e3b30fd282
    175 N752e92d28ee94c6c8e1a739dc184fbb6
    176 N9fc4a1d0db39498db69aae396bf3058e
    177 schema:sameAs https://app.dimensions.ai/details/publication/pub.1092735344
    178 https://doi.org/10.1186/s12967-017-1341-2
    179 schema:sdDatePublished 2022-11-24T21:01
    180 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    181 schema:sdPublisher Nf39a95280b88483192a5a8a9e0db170e
    182 schema:url https://doi.org/10.1186/s12967-017-1341-2
    183 sgo:license sg:explorer/license/
    184 sgo:sdDataset articles
    185 rdf:type schema:ScholarlyArticle
    186 N0c4e639313e542d68a8d94f3987a1d3e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    187 schema:name Immunotherapy
    188 rdf:type schema:DefinedTerm
    189 N148b11e4cf8141cbaf5464c98a956015 rdf:first sg:person.010720752277.37
    190 rdf:rest Nbe8dcf2cfce143e7a04c9c2052609d0d
    191 N1c7add0bfcbe4f4b995092c10258e3c6 rdf:first sg:person.01261361112.98
    192 rdf:rest N148b11e4cf8141cbaf5464c98a956015
    193 N1fe1373a85924b6fac0a4bda104461cf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    194 schema:name Cancer Vaccines
    195 rdf:type schema:DefinedTerm
    196 N23b405a1b0bf4cbabbce793eefe260b4 rdf:first sg:person.01236071027.04
    197 rdf:rest Nfc30e5e34ed94cca9a439fc5247e218d
    198 N26c329507caf4f6989edb1f105f237fc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    199 schema:name Precision Medicine
    200 rdf:type schema:DefinedTerm
    201 N30a65ba628204a2998da52e3b30fd282 schema:name dimensions_id
    202 schema:value pub.1092735344
    203 rdf:type schema:PropertyValue
    204 N349c3f5f1c3f4a959e5593cfae6feaa9 rdf:first sg:person.0637157757.45
    205 rdf:rest Nb50ca6e45dd044ae98fb5d61f7b40563
    206 N406d4bcda31a4aef92a1da79f893e36d rdf:first sg:person.01047232673.17
    207 rdf:rest N7f7313621bca48e585a9c463e8eee185
    208 N43a61abae6eb4980b1169ba5b1d406f4 rdf:first sg:person.0717300507.99
    209 rdf:rest N8c307982031f437e8d71c675ec5390e3
    210 N4e9c4810ec78431f90c7ff287cc7ddc4 rdf:first sg:person.053601122.01
    211 rdf:rest N705d94e9eeb046919af6ad3d6bff31c6
    212 N503d9e4754e94ffebaf23f98ea195264 rdf:first sg:person.01301465365.05
    213 rdf:rest Nfad4a4fe3d064990ac15e07467489d7f
    214 N705d94e9eeb046919af6ad3d6bff31c6 rdf:first sg:person.01240104744.46
    215 rdf:rest N23b405a1b0bf4cbabbce793eefe260b4
    216 N752e92d28ee94c6c8e1a739dc184fbb6 schema:name doi
    217 schema:value 10.1186/s12967-017-1341-2
    218 rdf:type schema:PropertyValue
    219 N79b273df1eb24e5fa4f26de6bf9592a7 schema:volumeNumber 15
    220 rdf:type schema:PublicationVolume
    221 N7cb8be9ddb124677be02834e032c3f54 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    222 schema:name Translational Research, Biomedical
    223 rdf:type schema:DefinedTerm
    224 N7d2adbe65f084e56a0573ac4e1bbdd6d rdf:first sg:person.010511471377.03
    225 rdf:rest N349c3f5f1c3f4a959e5593cfae6feaa9
    226 N7f7313621bca48e585a9c463e8eee185 rdf:first sg:person.01065663541.26
    227 rdf:rest N7d2adbe65f084e56a0573ac4e1bbdd6d
    228 N81f04996fa8a47688c72590ef9ba8158 rdf:first sg:person.01160762514.70
    229 rdf:rest Nca0507dc9d0a4a74994010ac1f4513b6
    230 N8c307982031f437e8d71c675ec5390e3 rdf:first sg:person.0663446543.06
    231 rdf:rest Nbc5bb6c03f2e4641b25d616b697cce7b
    232 N90f10fdb9a294e65914595d16595f9cc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    233 schema:name Italy
    234 rdf:type schema:DefinedTerm
    235 N93202783dd9543cc8f0d4b65a0580f4a rdf:first sg:person.01212502023.44
    236 rdf:rest N81f04996fa8a47688c72590ef9ba8158
    237 N95357cd44ef44f90936c3fd735ef3bd9 rdf:first sg:person.01207167603.25
    238 rdf:rest rdf:nil
    239 N9fb8bb4217944a4aa4cfdd5975b80f73 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    240 schema:name History, 21st Century
    241 rdf:type schema:DefinedTerm
    242 N9fc4a1d0db39498db69aae396bf3058e schema:name pubmed_id
    243 schema:value 29145885
    244 rdf:type schema:PropertyValue
    245 Na04430b6423e462898c3093423764b4e rdf:first sg:person.01101570400.85
    246 rdf:rest N406d4bcda31a4aef92a1da79f893e36d
    247 Nad1322073ede48ee93182e8d9f422663 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    248 schema:name Combined Modality Therapy
    249 rdf:type schema:DefinedTerm
    250 Nad72cc1e12f7405bb5c9eff893f51e27 rdf:first sg:person.01040377132.58
    251 rdf:rest N503d9e4754e94ffebaf23f98ea195264
    252 Nb24b7f528acc428ebf7ebae694735d38 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    253 schema:name Melanoma
    254 rdf:type schema:DefinedTerm
    255 Nb50ca6e45dd044ae98fb5d61f7b40563 rdf:first sg:person.07421203347.21
    256 rdf:rest N95357cd44ef44f90936c3fd735ef3bd9
    257 Nb6ca6a4d49bf45fba24358d14335c274 schema:issueNumber 1
    258 rdf:type schema:PublicationIssue
    259 Nbc5bb6c03f2e4641b25d616b697cce7b rdf:first sg:person.0640153517.24
    260 rdf:rest Na04430b6423e462898c3093423764b4e
    261 Nbe8dcf2cfce143e7a04c9c2052609d0d rdf:first sg:person.01221773122.43
    262 rdf:rest N4e9c4810ec78431f90c7ff287cc7ddc4
    263 Nca0507dc9d0a4a74994010ac1f4513b6 rdf:first sg:person.01275000143.77
    264 rdf:rest Nad72cc1e12f7405bb5c9eff893f51e27
    265 Nd0d9483b0d3545158e707e7cc2bdc3ce schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    266 schema:name Humans
    267 rdf:type schema:DefinedTerm
    268 Nd59e5ee1e58f4a809dd538fb751a8251 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    269 schema:name Systems Biology
    270 rdf:type schema:DefinedTerm
    271 Ndad0751c558c49e09dd3db447429b614 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    272 schema:name Lymphocytes, Tumor-Infiltrating
    273 rdf:type schema:DefinedTerm
    274 Ne0c2ae21e61548899321d79151302036 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    275 schema:name Biomedical Research
    276 rdf:type schema:DefinedTerm
    277 Ne4ebbb4426024e0283867d803a76fe58 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    278 schema:name T-Lymphocytes
    279 rdf:type schema:DefinedTerm
    280 Nf39a95280b88483192a5a8a9e0db170e schema:name Springer Nature - SN SciGraph project
    281 rdf:type schema:Organization
    282 Nfad4a4fe3d064990ac15e07467489d7f rdf:first sg:person.0757652731.20
    283 rdf:rest N1c7add0bfcbe4f4b995092c10258e3c6
    284 Nfc30e5e34ed94cca9a439fc5247e218d rdf:first sg:person.01154353457.84
    285 rdf:rest N43a61abae6eb4980b1169ba5b1d406f4
    286 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    287 schema:name Medical and Health Sciences
    288 rdf:type schema:DefinedTerm
    289 anzsrc-for:1107 schema:inDefinedTermSet anzsrc-for:
    290 schema:name Immunology
    291 rdf:type schema:DefinedTerm
    292 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
    293 schema:name Oncology and Carcinogenesis
    294 rdf:type schema:DefinedTerm
    295 sg:grant.2411268 http://pending.schema.org/fundedItem sg:pub.10.1186/s12967-017-1341-2
    296 rdf:type schema:MonetaryGrant
    297 sg:grant.2438793 http://pending.schema.org/fundedItem sg:pub.10.1186/s12967-017-1341-2
    298 rdf:type schema:MonetaryGrant
    299 sg:grant.4055452 http://pending.schema.org/fundedItem sg:pub.10.1186/s12967-017-1341-2
    300 rdf:type schema:MonetaryGrant
    301 sg:journal.1032886 schema:issn 1479-5876
    302 schema:name Journal of Translational Medicine
    303 schema:publisher Springer Nature
    304 rdf:type schema:Periodical
    305 sg:person.01040377132.58 schema:affiliation grid-institutes:grid.5386.8
    306 schema:familyName Demaria
    307 schema:givenName Sandra
    308 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01040377132.58
    309 rdf:type schema:Person
    310 sg:person.01047232673.17 schema:affiliation grid-institutes:grid.21107.35
    311 schema:familyName Taube
    312 schema:givenName Janis M.
    313 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01047232673.17
    314 rdf:type schema:Person
    315 sg:person.010511471377.03 schema:affiliation grid-institutes:grid.410305.3
    316 schema:familyName Stroncek
    317 schema:givenName David F.
    318 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010511471377.03
    319 rdf:type schema:Person
    320 sg:person.01065663541.26 schema:affiliation grid-institutes:grid.5254.6
    321 schema:familyName Thor Straten
    322 schema:givenName Per
    323 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01065663541.26
    324 rdf:type schema:Person
    325 sg:person.010720752277.37 schema:affiliation grid-institutes:grid.5386.8
    326 schema:familyName Formenti
    327 schema:givenName Silvia C.
    328 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010720752277.37
    329 rdf:type schema:Person
    330 sg:person.01101570400.85 schema:affiliation grid-institutes:grid.412639.b
    331 schema:familyName Sondel
    332 schema:givenName Paul
    333 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01101570400.85
    334 rdf:type schema:Person
    335 sg:person.01154353457.84 schema:affiliation grid-institutes:grid.14925.3b
    336 schema:familyName Mir
    337 schema:givenName Lluis M.
    338 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01154353457.84
    339 rdf:type schema:Person
    340 sg:person.01160762514.70 schema:affiliation grid-institutes:None
    341 schema:familyName Agarwala
    342 schema:givenName Sanjiv S.
    343 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01160762514.70
    344 rdf:type schema:Person
    345 sg:person.01207167603.25 schema:affiliation grid-institutes:grid.429651.d
    346 schema:familyName Thurin
    347 schema:givenName Magdalena
    348 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01207167603.25
    349 rdf:type schema:Person
    350 sg:person.01212502023.44 schema:affiliation grid-institutes:grid.508451.d
    351 schema:familyName Ascierto
    352 schema:givenName Paolo A.
    353 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01212502023.44
    354 rdf:type schema:Person
    355 sg:person.01221773122.43 schema:affiliation grid-institutes:grid.10392.39
    356 schema:familyName Garbe
    357 schema:givenName Claus
    358 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01221773122.43
    359 rdf:type schema:Person
    360 sg:person.01236071027.04 schema:affiliation grid-institutes:grid.170205.1
    361 schema:familyName Luke
    362 schema:givenName Jason J.
    363 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01236071027.04
    364 rdf:type schema:Person
    365 sg:person.01240104744.46 schema:affiliation grid-institutes:grid.410427.4
    366 schema:familyName Khleif
    367 schema:givenName Samir
    368 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01240104744.46
    369 rdf:type schema:Person
    370 sg:person.01261361112.98 schema:affiliation grid-institutes:grid.32224.35
    371 schema:familyName Ferrone
    372 schema:givenName Soldano
    373 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01261361112.98
    374 rdf:type schema:Person
    375 sg:person.01275000143.77 schema:affiliation grid-institutes:grid.417520.5
    376 schema:familyName Ciliberto
    377 schema:givenName Gennaro
    378 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01275000143.77
    379 rdf:type schema:Person
    380 sg:person.01301465365.05 schema:affiliation grid-institutes:grid.412004.3
    381 schema:familyName Dummer
    382 schema:givenName Reinhard
    383 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01301465365.05
    384 rdf:type schema:Person
    385 sg:person.053601122.01 schema:affiliation grid-institutes:grid.47100.32
    386 schema:familyName Halaban
    387 schema:givenName Ruth
    388 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.053601122.01
    389 rdf:type schema:Person
    390 sg:person.0637157757.45 schema:affiliation grid-institutes:grid.240145.6
    391 schema:familyName Wargo
    392 schema:givenName Jennifer A.
    393 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0637157757.45
    394 rdf:type schema:Person
    395 sg:person.0640153517.24 schema:affiliation grid-institutes:grid.240614.5
    396 schema:familyName Puzanov
    397 schema:givenName Igor
    398 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0640153517.24
    399 rdf:type schema:Person
    400 sg:person.0663446543.06 schema:affiliation grid-institutes:grid.5386.8
    401 schema:familyName Postow
    402 schema:givenName Michael
    403 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0663446543.06
    404 rdf:type schema:Person
    405 sg:person.0717300507.99 schema:affiliation grid-institutes:grid.240145.6
    406 schema:familyName Overwijk
    407 schema:givenName Willem W.
    408 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0717300507.99
    409 rdf:type schema:Person
    410 sg:person.07421203347.21 schema:affiliation grid-institutes:grid.21925.3d
    411 schema:familyName Zarour
    412 schema:givenName Hassane
    413 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07421203347.21
    414 rdf:type schema:Person
    415 sg:person.0757652731.20 schema:affiliation grid-institutes:grid.14925.3b
    416 schema:familyName Duong
    417 schema:givenName Connie P. M.
    418 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0757652731.20
    419 rdf:type schema:Person
    420 sg:pub.10.1007/s00262-006-0183-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041326514
    421 https://doi.org/10.1007/s00262-006-0183-1
    422 rdf:type schema:CreativeWork
    423 sg:pub.10.1007/s00262-015-1727-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1010648370
    424 https://doi.org/10.1007/s00262-015-1727-z
    425 rdf:type schema:CreativeWork
    426 sg:pub.10.1007/s00262-016-1856-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1039598355
    427 https://doi.org/10.1007/s00262-016-1856-z
    428 rdf:type schema:CreativeWork
    429 sg:pub.10.1007/s10555-016-9615-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005576880
    430 https://doi.org/10.1007/s10555-016-9615-3
    431 rdf:type schema:CreativeWork
    432 sg:pub.10.1038/nature11183 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053677952
    433 https://doi.org/10.1038/nature11183
    434 rdf:type schema:CreativeWork
    435 sg:pub.10.1038/nature14404 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002745775
    436 https://doi.org/10.1038/nature14404
    437 rdf:type schema:CreativeWork
    438 sg:pub.10.1038/nbt.3520 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042966935
    439 https://doi.org/10.1038/nbt.3520
    440 rdf:type schema:CreativeWork
    441 sg:pub.10.1038/nbt.3662 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036461196
    442 https://doi.org/10.1038/nbt.3662
    443 rdf:type schema:CreativeWork
    444 sg:pub.10.1038/ncomms15618 schema:sameAs https://app.dimensions.ai/details/publication/pub.1085940279
    445 https://doi.org/10.1038/ncomms15618
    446 rdf:type schema:CreativeWork
    447 sg:pub.10.1038/ng.2359 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021618497
    448 https://doi.org/10.1038/ng.2359
    449 rdf:type schema:CreativeWork
    450 sg:pub.10.1038/ni.2608 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043661049
    451 https://doi.org/10.1038/ni.2608
    452 rdf:type schema:CreativeWork
    453 sg:pub.10.1038/nm.3105 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008050192
    454 https://doi.org/10.1038/nm.3105
    455 rdf:type schema:CreativeWork
    456 sg:pub.10.1038/nmeth.3337 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004732944
    457 https://doi.org/10.1038/nmeth.3337
    458 rdf:type schema:CreativeWork
    459 sg:pub.10.1038/nri3799 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048881672
    460 https://doi.org/10.1038/nri3799
    461 rdf:type schema:CreativeWork
    462 sg:pub.10.1038/onc.2012.160 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007888310
    463 https://doi.org/10.1038/onc.2012.160
    464 rdf:type schema:CreativeWork
    465 sg:pub.10.1186/1479-5876-10-85 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050474099
    466 https://doi.org/10.1186/1479-5876-10-85
    467 rdf:type schema:CreativeWork
    468 sg:pub.10.1186/1479-5876-11-180 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051715774
    469 https://doi.org/10.1186/1479-5876-11-180
    470 rdf:type schema:CreativeWork
    471 sg:pub.10.1186/1479-5876-11-61 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013247656
    472 https://doi.org/10.1186/1479-5876-11-61
    473 rdf:type schema:CreativeWork
    474 sg:pub.10.1186/1479-5876-13-s1-o11 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014959746
    475 https://doi.org/10.1186/1479-5876-13-s1-o11
    476 rdf:type schema:CreativeWork
    477 sg:pub.10.1186/2051-1426-1-11 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011304979
    478 https://doi.org/10.1186/2051-1426-1-11
    479 rdf:type schema:CreativeWork
    480 sg:pub.10.1186/2051-1426-3-s2-p246 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005776800
    481 https://doi.org/10.1186/2051-1426-3-s2-p246
    482 rdf:type schema:CreativeWork
    483 sg:pub.10.1186/2051-1426-3-s2-p343 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040645387
    484 https://doi.org/10.1186/2051-1426-3-s2-p343
    485 rdf:type schema:CreativeWork
    486 sg:pub.10.1186/s40425-016-0156-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011176694
    487 https://doi.org/10.1186/s40425-016-0156-7
    488 rdf:type schema:CreativeWork
    489 sg:pub.10.1186/s40425-016-0160-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1005751518
    490 https://doi.org/10.1186/s40425-016-0160-y
    491 rdf:type schema:CreativeWork
    492 sg:pub.10.1186/s40425-017-0266-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1090960408
    493 https://doi.org/10.1186/s40425-017-0266-x
    494 rdf:type schema:CreativeWork
    495 sg:pub.10.1245/s10434-014-4169-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009814101
    496 https://doi.org/10.1245/s10434-014-4169-5
    497 rdf:type schema:CreativeWork
    498 sg:pub.10.1245/s10434-016-5376-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1031102571
    499 https://doi.org/10.1245/s10434-016-5376-z
    500 rdf:type schema:CreativeWork
    501 sg:pub.10.1684/ejd.2015.2522 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025373346
    502 https://doi.org/10.1684/ejd.2015.2522
    503 rdf:type schema:CreativeWork
    504 sg:pub.10.2165/00007256-200838040-00002 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015129676
    505 https://doi.org/10.2165/00007256-200838040-00002
    506 rdf:type schema:CreativeWork
    507 grid-institutes:None schema:alternateName Oncology & Hematology, St. Luke’s University Hospital and Temple University, Bethlehem, PA, USA
    508 schema:name Oncology & Hematology, St. Luke’s University Hospital and Temple University, Bethlehem, PA, USA
    509 rdf:type schema:Organization
    510 grid-institutes:grid.10392.39 schema:alternateName Division of Dermatologic Oncology, Department of Dermatology, Eberhard Karls University, Tübingen, Germany
    511 schema:name Division of Dermatologic Oncology, Department of Dermatology, Eberhard Karls University, Tübingen, Germany
    512 rdf:type schema:Organization
    513 grid-institutes:grid.14925.3b schema:alternateName CNRS (National Center for Scientific Research, France), University Paris-Saclay, Gustave Roussy, Villejuif, France
    514 INSERM (National Institute of Health and Medical Research), Institut Gustave Roussy, Villejuif, France
    515 schema:name CNRS (National Center for Scientific Research, France), University Paris-Saclay, Gustave Roussy, Villejuif, France
    516 INSERM (National Institute of Health and Medical Research), Institut Gustave Roussy, Villejuif, France
    517 rdf:type schema:Organization
    518 grid-institutes:grid.170205.1 schema:alternateName Department of Hematology/Oncology, University of Chicago Comprehensive Cancer Center, Chicago, IL, USA
    519 schema:name Department of Hematology/Oncology, University of Chicago Comprehensive Cancer Center, Chicago, IL, USA
    520 rdf:type schema:Organization
    521 grid-institutes:grid.21107.35 schema:alternateName Johns Hopkins University School of Medicine, Baltimore, MD, USA
    522 schema:name Johns Hopkins University School of Medicine, Baltimore, MD, USA
    523 rdf:type schema:Organization
    524 grid-institutes:grid.21925.3d schema:alternateName Medicine, Immunology and Dermatology Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    525 schema:name Medicine, Immunology and Dermatology Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    526 rdf:type schema:Organization
    527 grid-institutes:grid.240145.6 schema:alternateName Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    528 Division of Cancer Medicine, Department of Melanoma Medical Oncology-Research, University of Texas MD Anderson Cancer Center, Houston, TX, USA
    529 schema:name Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    530 Division of Cancer Medicine, Department of Melanoma Medical Oncology-Research, University of Texas MD Anderson Cancer Center, Houston, TX, USA
    531 rdf:type schema:Organization
    532 grid-institutes:grid.240614.5 schema:alternateName Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA
    533 schema:name Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA
    534 rdf:type schema:Organization
    535 grid-institutes:grid.32224.35 schema:alternateName Massachusetts General Hospital, Boston, MA, USA
    536 schema:name Massachusetts General Hospital, Boston, MA, USA
    537 rdf:type schema:Organization
    538 grid-institutes:grid.410305.3 schema:alternateName Clinical Center, National Institutes of Health, Bethesda, MD, USA
    539 schema:name Clinical Center, National Institutes of Health, Bethesda, MD, USA
    540 rdf:type schema:Organization
    541 grid-institutes:grid.410427.4 schema:alternateName Georgia Cancer Center, Augusta University, Augusta, GA, USA
    542 schema:name Georgia Cancer Center, Augusta University, Augusta, GA, USA
    543 rdf:type schema:Organization
    544 grid-institutes:grid.412004.3 schema:alternateName Department of Dermatology, University of Zurich Hospital, Zurich, Switzerland
    545 schema:name Department of Dermatology, University of Zurich Hospital, Zurich, Switzerland
    546 rdf:type schema:Organization
    547 grid-institutes:grid.412639.b schema:alternateName UW Carbone Cancer Center, Madison, WI, USA
    548 schema:name Pediatrics, Human Oncology and Genetics, University of Wisconsin, Madison, WI, USA
    549 UW Carbone Cancer Center, Madison, WI, USA
    550 rdf:type schema:Organization
    551 grid-institutes:grid.417520.5 schema:alternateName IRCCS “Regina Elena” National Cancer Institute, Rome, Italy
    552 schema:name IRCCS “Regina Elena” National Cancer Institute, Rome, Italy
    553 rdf:type schema:Organization
    554 grid-institutes:grid.429651.d schema:alternateName Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, NCI, NIH, Rockville, MD, USA
    555 schema:name Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, NCI, NIH, Rockville, MD, USA
    556 rdf:type schema:Organization
    557 grid-institutes:grid.47100.32 schema:alternateName Department of Dermatology, Yale University School of Medicine, New Haven, CT, USA
    558 schema:name Department of Dermatology, Yale University School of Medicine, New Haven, CT, USA
    559 rdf:type schema:Organization
    560 grid-institutes:grid.508451.d schema:alternateName Istituto Nazionale Tumori di Napoli Fondazione “G. Pascale”, Via Mariano Semmola, 80131, Naples, Italy
    561 schema:name Istituto Nazionale Tumori di Napoli Fondazione “G. Pascale”, Via Mariano Semmola, 80131, Naples, Italy
    562 Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, IRCCS Istituto Nazionale Tumori “Fondazione G. Pascale”, Naples, Italy
    563 rdf:type schema:Organization
    564 grid-institutes:grid.5254.6 schema:alternateName Department of Immunology and Microbiology, University of Copenhagen, Herlev, Denmark
    565 schema:name Center for Cancer Immune Therapy (CCIT), Department of Hematology, University Hospital Herlev, Herlev, Denmark
    566 Department of Immunology and Microbiology, University of Copenhagen, Herlev, Denmark
    567 rdf:type schema:Organization
    568 grid-institutes:grid.5386.8 schema:alternateName Department of Radiation Oncology, Weill Cornell Medical College, New York City, NY, USA
    569 Radiation Oncology and Pathology, Weill Cornell Medical College, New York City, NY, USA
    570 Weill Cornell Medical College, New York, NY, USA
    571 schema:name Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, NY, USA
    572 Department of Radiation Oncology, Weill Cornell Medical College, New York City, NY, USA
    573 Radiation Oncology and Pathology, Weill Cornell Medical College, New York City, NY, USA
    574 Weill Cornell Medical College, New York, NY, USA
    575 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...